Spike Protein News and Research

RSS

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

Research uncovers SARS-CoV-2 viral traits critical for the virus in human airways

A new study published on the preprint server bioRxiv* in October 2020 reports the discovery of important viral genomic features that are crucial to its replication in the human airway cells, and its enhancing mutations which increase the rate of replication and determine its target cells.

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

NRP-1 receptor potentiates SARS-CoV-2 infectivity

The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.

26 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020

Graphene-enhanced PPE for COVID-19

To tackle this need, nanotechnology researchers from Italy have suggested using bidimensional graphene to improve existing PPE kits. Their research is published on the preprint server medRxiv.

25 Oct 2020

Neuropilin-1: A new route of SARS-CoV-2 entry

A new study published in the reputed journal Science in October 2020 reports the potential therapeutic value of the second type of host transmembrane receptor, called neuropilins, which attach to the spike protein of SARS-CoV-2 and may enhance its infectivity.

25 Oct 2020

Scientists devise new method to map HIV's sugary shield in unprecedented detail

Scientists from Scripps Research and Los Alamos National Laboratory have devised a method for mapping in unprecedented detail the thickets of slippery sugar molecules that help shield HIV from the immune system.

23 Oct 2020

ACROBiosystems and the Fight Against COVID-19

In this interview, Dr. Yinang Jiang discusses ACROBiosystems and their efforts in the fight against COVID-19 and the search for a vaccine

From ACROBiosystems 23 Oct 2020

Researchers develop lab-grown lung model to study SARS-CoV-2 infection

A team of Duke University researchers has developed a lab-grown living lung model that mimics the tiny air sacs of the lungs where coronavirus infection and serious lung damage take place.

23 Oct 2020

Researchers develop a novel method to test for COVID-19 antibodies

When Dr. Stephen Smith of Seattle Children's Research Institute came down with muscle aches, gastrointestinal distress and a sudden loss of smell in late February, he suspected he had COVID-19.

23 Oct 2020

Initial lockdown in France substantially curbed COVID-19, but many remain susceptible to the virus

Now, a new study by researchers at the Santé Publique France conducted seroprevalence estimates in France, one of the countries with high COVID-19 cases in Europe.

22 Oct 2020

DNA vaccine-induced antibodies neutralize SARS-CoV-2

The coronavirus disease (COVID-19) is far from over as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage across the globe. With the vast spread of the virus, many countries who reported flattening the curve over the past months have reported clusters of new cases and second waves of the outbreak.

22 Oct 2020

Study may help develop effective therapeutic strategies against COVID-19

People have different susceptibilities to SARS-CoV-2, the virus behind the COVID-19 pandemic, and develop varying degrees of fever, fatigue, and breathing problems -- common symptoms of the illness. What might explain this variation?

22 Oct 2020

Researchers use molecular dynamics simulations to identify secrets of SARS-CoV-2 virus

The virus wreaking havoc on our lives is an efficient infection machine. Comprised of only 29 proteins (compared to our 400,000), with a genome 1/200,000 the size of ours, SARS-CoV-2 is expertly evolved to trick our cells to contribute its machinery to assist in its propagation.

22 Oct 2020

SARS-CoV-2 mutations dictate severity of COVID-19 disease

A recent study by researchers from Semmelweis University and Pazmany Peter Catholic University in Budapest, Hungary, published on the preprint server medRxiv in October 2020, shows the relationship of specific mutations on the disease's outcome.

22 Oct 2020

SARS-CoV-2 mutations possibly making virus less virulent

In their bioRxiv* preprint paper, the researchers focus on mapping the clade-specific mutations' effects on the protein structures' conformation and stability. They identified the mutations in the set of seven proteins - orf8, nsp2, nsp4, nsp6, nucleocapsid protein (N), and Spike protein (S).

21 Oct 2020

"Immunological imprinting" could influence antibody response to COVID-19

Researchers in the United States and Spain have shown that prior exposure to seasonal coronaviruses may influence antibody responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19).

21 Oct 2020

Spike protein of SARS-CoV-2 virus identifies and binds neuropilin-1 on human cells to infect them

Helping to explain what makes SARS-CoV-2 so capable of infecting human cells, researchers in two independent studies discovered that the virus's spike protein recognizes and binds a protein on the human cell surface called neuropilin-1.

21 Oct 2020